Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 16, 2015 - Issue 14
Submit an article Journal homepage
507
Views
7
CrossRef citations to date
0
Altmetric
Drug Evaluation

Future of combination therapy with dabrafenib and trametinib in metastatic melanoma

Yasaman ZiaUCSF Helen Diller Comprehensive Cancer Center, 1600 Divisadero Street, Room B708, San Francisco, CA 94115, USA+1 20 24 89 19 86; +1 41 55 14 69 69; [email protected]
, MPH,
Lawrence ChenUCSF Helen Diller Comprehensive Cancer Center, 1600 Divisadero Street, Room B708, San Francisco, CA 94115, USA
, MS (Cutaneous Oncology Clinical Trial Coordinator) &
Adil DaudUCSF Helen Diller Comprehensive Cancer Center, 1600 Divisadero Street, Room B708, San Francisco, CA 94115, USA
, MD (Cutaneous Oncologist)
Pages 2257-2263 | Published online: 31 Aug 2015

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Amélie Boespflug & Luc Thomas. (2016) Cobimetinib and vemurafenib for the treatment of melanoma. Expert Opinion on Pharmacotherapy 17:7, pages 1005-1011.
Read now

Articles from other publishers (6)

Hongjian Li, Cheng Huang, Zongliang Zhang, Yunyu Feng, Zeng Wang, Xin Tang, Kunhong Zhong, Yating Hu, Gang Guo, Liangxue Zhou, Wenhao Guo, Jianguo Xu, Hui Yang & Aiping Tong. (2020) MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody. Frontiers in Oncology 10.
Crossref
Sanne Huijberts, Liqin Wang, Rodrigo Leite de Oliveira, Hilde Rosing, Bastiaan Nuijen, Jos Beijnen, Rene Bernards, Jan Schellens & Sofie Wilgenhof. (2020) Vorinostat in patients with resistant BRAF V600E mutated advanced melanoma: a proof of concept study . Future Oncology 16:11, pages 619-629.
Crossref
Jeffrey R. Infante, Roger B. Cohen, Kevin B. Kim, Howard A. BurrisIIIIII, Gregory Curt, Ugochi Emeribe, Delyth Clemett, Helen K. Tomkinson & Patricia M. LoRusso. (2017) A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. Investigational New Drugs 35:5, pages 576-588.
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 531 559 .
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 505 530 .
Sofia Oliveira, Pedro Coelho, Cristina Prudêncio, Mónica Vieira, Raquel Soares, Susana G. Guerreiro & Rúben Fernandes. (2016) Melanoma and obesity: Should antioxidant vitamins be addressed?. Life Sciences 165, pages 83-90.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.